How to read and use this page
This page is the detail of the medical field's "Technology Seeds (companies' manufacturing technologies)". It compiles what it is about along with related market and regulatory information. For first-time visitors, it explains how to read it and how to operate it.
The content listed
- Challenge: What you are struggling with (Technology overview)
- Market data: Production value of related medical devices, etc. (actual data from national official statistics).
- Situation and voices from the field: The likely state of the medical field and a brief voice (reference information generated automatically by AI).
- Solution hypothesis: Possible solution ideas (generated automatically by AI).
- Related Seeds: Similar themes
* Content generated by AI (voices from the field, solutions, etc.) is reference information. For final medical and regulatory decisions, always confirm with official sources or specialists.
View the how-to guide
Precision laser drilling machine capable of reducing machining errors to one-tenth of conventional levels (Test Seeds 1)
AI translated
- General Surgery
- Plastic Surgery / Dermatology / Wound Care
- Orthopedics
This is a precision laser drilling machine capable of reducing machining errors to one-tenth of conventional levels for both metal and resin materials. Delivery is possible within one week of ordering. It achieves one-third of the conventional cost. The precision laser processing machine is equipped with AI, which automatically calculates the optimal angle, distance, and intensity, allowing for laser irradiation optimized for the processing required by the customer. The main unit is lightweight and portable. It is equipped with a mechanism to cancel vibrations even if they occur at the installation site, ensuring proper correction and enabling processing with optimal performance at all times. (Text information on the overview of needs/seeds)
本装置は日本発の最先端技術であり、自動車産業のほか、半導体や医療機器分野でも活用が見込まれる。(補足情報:概要の下につづけて表示されるテキスト情報)

Market Data
Visually present statistics related to the Needs
Market size trend of related devicesTrends in the production value of expected related devices (Statistics of Production by Pharmaceutical Industry)
Data source:Pharmaceutical Industry Production Statistics (MHLW) / e-Stat, portal for government statistics
View this Needs' related charts (market, disease, provision system) all together →
Approval and reimbursement
Case examples for SaMD applicability determination
Reference for cases where this need/solution involves software or AI. Actual cases judged "applicable / not applicable" as a medical device (MHLW case database). Always confirm final applicability with official sources and experts.
-
該当
糖尿病を伴う複数疾患を有する高齢者に対する栄養療法支援アプリ・糖尿病を伴う複数疾患を有した患者に対する栄養療法のため、食事療法に関する最適なデータを算出し、推奨される指導...
-
該当
ウェアラブル製品心電図や血圧を計測し、疾病の有無を判断する。
-
該当
新型コロナウイルス重症化予後予測アプリ疾病の重症度を判定し、最適な治療介入に寄与するプログラムである。
-
非該当
安否確認プログラム疾病の診断・予防を行うものではなく、生存確認・異常確認のためだけに使用するプログラムである。
-
非該当
パーキンソン病症状管理支援プログラムクラスⅠ医療機器相当のプログラムである。
-
非該当
健康管理用プログラムデータの記録及び管理が目的であり、疾病の診断または評価をしない。
Related patents
These are patents that may be related to this Needs/technology. Sources: Japan Patent Office Patent Information Acquisition API / Google Patents.
The details of this solution could not be loaded. Check your connection and try again.
Needs × Solution Hypothesis
Assumed elemental technologies
Market for this solution (production value, official statistics)
Related regulatory notices (PMDA)
Regulatory approval process flow (Japan, US, EU, ASEAN)
Highlights the class-classification guideline equivalent to "Class Ⅱ". Actual classification and pathway differ depending on the product's characteristics and each jurisdiction's regulations. Please always confirm with official information and experts.
JapanPMDA / Ministry of Health, Labour and Welfare
- General medical devices → Manufacturing/marketing notification
- Controlled medical device → third-party certification (with standards) / ministerial approval
- High-risk control → PMDA review → MHLW Minister approval
- High-risk control (high risk) → PMDA review → Minister approval
View required documents and items
- Approval application / STED (Summary Technical Documentation)
- Intended use & effect
- Shape, structure & principle
- Raw materials & ingredients
- Performance & specs
- Non-clinical testing (biological safety, electrical safety, EMC, performance, stability)
- Risk analysis (ISO 14971)
- Clinical trial results (when novelty is high)
- Manufacturing method & facility
- Documents on QMS conformity
- Package insert (draft)
QMS conformity inspection and marketing authorization required
United StatesFDA
- Class I → mostly Exempt (registration/listing).
- Class II → 510(k) / De Novo for novel devices.
- Class III → PMA (premarket approval)
- Class III equivalent → PMA
View required documents and items
- Grounds for equivalence (Predicate device) / substantial equivalence (510(k))
- Indications for Use
- Device Description
- Performance data (bench / animal)
- Biocompatibility
- Software documentation (if applicable)
- Sterilization and expiry period
- Labeling
- (De Novo) classification request & special controls
- (PMA) clinical trial data & manufacturing information
Facility registration, QMSR (quality), and, if needed, an IDE clinical trial
EuropeEU MDR (2017/745)
- Class I → self-declaration of conformity → CE mark
- Class IIa/IIb → Notified Body involvement → CE.
- Class III → NB (design review) → CE
- Class III → NB (high risk) → CE
View required documents and items
- Technical documentation (Annex II/III)
- General Safety and Performance Requirements (GSPR) checklist
- Risk management (ISO 14971)
- Design & manufacturing information
- Clinical Evaluation Report (CER)
- Post-market surveillance (PMS) plan & PMCF
- Labeling & IFU
- UDI / EUDAMED registration
- Declaration of Conformity (DoC)
Technical documentation, clinical evaluation, UDI & EUDAMED registration
ASEANAMDD (national authorities)
- Class A (low) → registration/notification
- Class B → CSDT submission/registration
- Class C → evaluation/registration
- Class D (high) → detailed evaluation/approval
View required documents and items
- CSDT (common submission format)
- Executive summary
- Essential Principles checklist
- Device description and specifications
- Design verification & validation
- Clinical evidence
- Risk management
- Labeling
- Manufacturer information & QMS (ISO 13485)
Apply to each country (Thailand / Malaysia / Singapore, etc.) using the CSDT format.
The flow of insurance listing and insurance points (Japan / Ministry of Health, Labour and Welfare, Chuikyo)
This is a guide to whether this device/technology can be calculated under existing insurance fee points, and to the flow for newly acquiring one if not. The actual category depends on Chuikyo's evaluation.
- ① Check whether it falls under existing fee points: If an equivalent already-listed material/technology exists, it is calculated under an existing category of designated insured medical materials (Category B) or under an existing technical fee (Category A = included in the technical fee).
- ② New acquisition for new functions/technologies: A function not in existing listings = Category C1 (new function) / involving new technology = Category C2 (new function and new technology).
- ③ Submit an insurance-application request (after regulatory approval) → assessed by the Chuikyo Specialized Organization for Insured Medical Materials.
- ④ Price calculation: Comparison with a similar functional category (compared against a similar already-listed product) / cost-accounting method.
- ⑤ Notification and listing: Insurance coverage begins at one of several listing opportunities held each year.
* Whether specific applicable fee points exist requires cross-checking against the "Medical Service Fee Schedule (designated insured medical materials, surgery/procedures)" (being addressed progressively).
Cautions at commercialization (advertising regulations)
These are the main points to note during commercialization and promotion, based on the Pharmaceuticals and Medical Devices Act and the Medical Advertising Guidelines. The applicable scope varies depending on the nature of the solution.
- ① Ban on advertising unapproved products (Article 68 of the Pharmaceuticals and Medical Devices Act): Before approval, certification, or notification, advertising that names a product and promotes its efficacy or performance is prohibited. Be careful with communications at the research stage.
- ② Ban on exaggerated advertising (Article 66 of the Pharmaceuticals and Medical Devices Act): Regarding efficacy, performance, and safety, expressions that are contrary to fact or exaggerated, and superlative expressions (unsubstantiated claims such as "best" or "No.1") are not allowed.
- ③ Promotion within the approved scope: The intended use and efficacy that can be claimed are limited to what is granted by the approval/certification. Do not promote off-label uses.
- ④ Notes on Software as a Medical Device (SaMD): The performance of AI/software (accuracy, positioning as diagnostic support) must be described within the approved scope. Be careful with assertions such as "diagnoses" or expressions that substitute for a physician's judgment.
- ⑤ Regulatory differences by audience: The scope of advertising regulation differs for the general public versus healthcare professionals. Advertising by medical institutions must also follow the "Medical Advertising Guidelines" (restrictions on testimonials, before-and-after images, and comparative superiority advertising).
Source: Medical advertising regulations (MHLW) ↗ / PMD Act, Articles 66 and 68
Refer to similar approval review reports
Especially for higher-class medical devices and "new medical devices" (including cases where a Class II device was approved as a new medical device), the approval review reports of similar past devices are extremely useful for application strategy, evaluation items, and reviewing non-clinical/clinical data. You can search for the actual reports by the expected generic name below.
Search related clinical trials
Knowing what clinical trials and research are being conducted for similar solutions is useful for development planning, evidence design, and understanding competitors. You can search in Japan (jRCT / UMIN-CTR) and overseas (ClinicalTrials.gov).
On-site situation and voices (VOC)
Voices from the field